PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsLintuzumab
Lintuzumab
Lintuzumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against myeloid cell surface antigen CD33.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
22 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938—C95871——15
Myeloid leukemia acuteD015470—C92.0861——11
Myeloid leukemiaD007951—C92621——8
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myelodysplastic syndromesD009190—D4675———10
PreleukemiaD011289——54———8
SyndromeD013577——54———8
Myeloproliferative disordersD009196—D47.141———4
Promyelocytic leukemia acuteD015473—C92.4—2———2
Myelodysplastic-myeloproliferative diseasesD054437——21———2
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340—11———2
NeutropeniaD009503—D70—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myelomonocytic leukemia chronicD015477—C93.12————2
Myelomonocytic leukemia juvenileD054429—C93.32————2
Multiple myelomaD009101—C90.01————1
Plasma cell neoplasmsD054219——1————1
AnemiaD000740HP_0001903D64.91————1
Refractory anemia with excess of blastsD000754—D46.21————1
Refractory anemiaD000753——1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLintuzumab
INNlintuzumab
Description
Lintuzumab (humanized mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL2109150
ChEBI ID—
PubChem CID—
DrugBank—
UNII IDV00Y10W60W (ChemIDplus, GSRS)
Target
Agency Approved
CD33
CD33
Organism
Homo sapiens
Gene name
CD33
Gene synonyms
SIGLEC3
NCBI Gene ID
Protein name
myeloid cell surface antigen CD33
Protein synonyms
CD33, CD33 antigen (gp67), CD33 molecule transcript, gp67, Sialic acid-binding Ig-like lectin 3, Siglec-3
Uniprot ID
Mouse ortholog
Cd33 (12489)
myeloid cell surface antigen CD33 (Q63997)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 527 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
72 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use